Mylan Looks To Extend Intellectual Property Protection For Beta Blocker Nebivolol
This article was originally published in The Pink Sheet Daily
Executive Summary
The company anticipates protection beyond the compound patent, which expires in 2020. The NDA for the antihypertensive was filed April 30.
You may also be interested in...
Bertek Submits NDA For Nebivolol; Beta Blocker Would Be Firm’s Third Branded Antihypertensive
The Mylan subsidiary claims patent protection into 2020 for nebivolol, a cardioselective beta blocker with vasodilating properties licensed from Janssen.
Bertek Apomorphine Clears FDA
Bertek Apokyn (apomorphine) clears FDA April 20 for subcutaneous injection to treat "off" episodes of Parkinson's disease
U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.